Skip to content
OVistoaIntelligence index
AboutMethodologyPricingDocs
Sign inSign up
BREAKINGPerson found dead in car after it plows into health club in Portland, Oregon2 hr ago
Top StoriesUnited StatesCanadaWorldPoliticsGeneralBusinessTechHealthSportsAviationArtificial IntelligencePublishers

Real-Time Trial Review Needs a Response Plan, Not Just a Data Feed

1 articles · 1 outlets · spread 0.00

Real-Time Trial Review Needs a Response Plan, Not Just a Data Feed
FDA2 d ago

Real-Time Trial Review Needs a Response Plan, Not Just a Data Feed

Full coverage view across outlets, lean, source quality, and framing. Compare framing without algorithmic ranking.

1 articles1 outletsSpread 0.0012 claims
OVistoa

Article-level news analysis, transparent scoring, and API tools for readers, publishers, and teams that need source context.

DMCA and copyright review

Copyright owners can submit notices, counter-notices, and source material concerns through the dedicated review flow.

Open DMCA review

Product

  • Home
  • Feed
  • Search
  • Topics
  • Saved

Platform

  • About
  • Methodology
  • Home
  • Search
  • Saved
  • Me

From the Left

0 outlets

No coverage from this perspective yet.

From the Center

1 outlet
  • MedPage Today·May 1

    Real-Time Trial Review Needs a Response Plan, Not Just a Data Feed

    When the FDA announced recently that two drug companies had begun streaming clinical trial data to agency reviewers in real time, FDA Commissioner Marty Makary, MD, MPH, reached for an analogy from his own training. As a surgical oncologist, he watched his patients in the operating room and ICU on continuous monitors. When vitals dropped, the team intervened. Nobody waited for a report in the mail. Why, he asked, should regulatory oversight of experimental drugs be any different? It's a good analogy. It also gives away more than the announcement intends. Real-time data is not the same thing as real-time oversight. A monitor that beeps in an empty hospital hallway is not a clinical safeguard, and a data feed that arrives at FDA without a defined plan for who acts on it, when, and how is not regulatory review. The challenge in continuous monitoring has never been getting the data. It has been deciding what to do about it. The announcement describes, in detail, a system that delivers signals faster. But right now, it says little about what happens when one arrives. That gap is something we should be watching as this initiative evolves. We have spent decades learning what

From the Right

0 outlets

No coverage from this perspective yet.

Claim synthesis

Pro users see canonical claims across the cluster and which outlets reported each one.

Learn more

Outlets covering this story

MedPage Today

First seen

May 1, 2026

Latest

May 1, 2026

Outlets

1

Diversity

100/100

  • Pricing
  • API docs
  • Publishers

    • Account

    • Sign in
    • Create account
    • Reader settings
    • API console

    Legal

    • Terms
    • Privacy
    • Security
    • DMCA

    © 2026 Vistoa. All rights reserved.

    Limited excerpts, attribution, analysis, and outbound publisher links remain core product boundaries.